Compare TARS & MC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TARS | MC |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | 1416 |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.1B |
| IPO Year | 2020 | 2014 |
| Metric | TARS | MC |
|---|---|---|
| Price | $68.26 | $54.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 11 |
| Target Price | ★ $99.80 | $67.50 |
| AVG Volume (30 Days) | 652.8K | ★ 967.6K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 4.72% |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ 0.75 |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $61.17 | $14.07 |
| Revenue Next Year | $26.47 | $17.57 |
| P/E Ratio | ★ N/A | $73.35 |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $53.89 | $51.06 |
| 52 Week High | $91.53 | $78.22 |
| Indicator | TARS | MC |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 39.55 |
| Support Level | $60.95 | $51.06 |
| Resistance Level | $74.51 | $57.54 |
| Average True Range (ATR) | 3.34 | 2.00 |
| MACD | -0.37 | 0.17 |
| Stochastic Oscillator | 2.22 | 46.12 |
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.